Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials.
CNS
NGGCT
intracranial germ cell tumors
relapse
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
02 11 2022
02 11 2022
Historique:
pubmed:
27
2
2022
medline:
4
11
2022
entrez:
26
2
2022
Statut:
ppublish
Résumé
Central Nervous System Non-Germinomatous Germ Cell Tumors (CNS-NGGCT) are rare but curable tumors. Due to their rarity, patients with treatment failures remain a poorly characterized group with unfavorable outcomes. In this study, we sought to characterize patients with treatment failures in a large, prospectively treated cohort. European and North American clinical trials for patients with CNS-NGGCT (SIOP-GCT-96, SFOP-TGM-TC 90/92, COG-ACNS0122, and COG-ACNS1123) were pooled for analysis. Additionally, patients included and treated in the UK and France national registries under strict protocol guidelines were included as an independent, non-overlapping cohort. A total of 118 patients experienced a treatment failure. Twenty-four patients had progressive disease during therapy, and additional 11 patients were diagnosed with growing teratoma syndrome (GTS). Patients with GTS are significantly younger and present with local failures and negative tumor markers. Eighty-three individuals experienced disease relapses after treatment ended. Patients' metastatic relapses presented significantly earlier than local relapses and were associated with tumor marker elevation (OR: 4.39; P = .026). In our analysis, focal or whole-ventricular radiation therapy was not associated with an increased risk of metastatic relapses. Herein, we present the largest pooled dataset of prospectively treated patients with relapsed CNS-NGGCT. Our study identified younger age and negative tumor markers to be characteristic of GTS. Additionally, we elucidated that metastatic relapses occur earlier than local relapses are associated with elevated tumor markers and are not associated with the field of radiation therapy. These findings are of utmost importance for the planning of future clinical trials and the implementation of surveillance strategies in these patients.
Sections du résumé
BACKGROUND
Central Nervous System Non-Germinomatous Germ Cell Tumors (CNS-NGGCT) are rare but curable tumors. Due to their rarity, patients with treatment failures remain a poorly characterized group with unfavorable outcomes. In this study, we sought to characterize patients with treatment failures in a large, prospectively treated cohort.
METHODS
European and North American clinical trials for patients with CNS-NGGCT (SIOP-GCT-96, SFOP-TGM-TC 90/92, COG-ACNS0122, and COG-ACNS1123) were pooled for analysis. Additionally, patients included and treated in the UK and France national registries under strict protocol guidelines were included as an independent, non-overlapping cohort.
RESULTS
A total of 118 patients experienced a treatment failure. Twenty-four patients had progressive disease during therapy, and additional 11 patients were diagnosed with growing teratoma syndrome (GTS). Patients with GTS are significantly younger and present with local failures and negative tumor markers. Eighty-three individuals experienced disease relapses after treatment ended. Patients' metastatic relapses presented significantly earlier than local relapses and were associated with tumor marker elevation (OR: 4.39; P = .026). In our analysis, focal or whole-ventricular radiation therapy was not associated with an increased risk of metastatic relapses.
CONCLUSIONS
Herein, we present the largest pooled dataset of prospectively treated patients with relapsed CNS-NGGCT. Our study identified younger age and negative tumor markers to be characteristic of GTS. Additionally, we elucidated that metastatic relapses occur earlier than local relapses are associated with elevated tumor markers and are not associated with the field of radiation therapy. These findings are of utmost importance for the planning of future clinical trials and the implementation of surveillance strategies in these patients.
Identifiants
pubmed: 35218656
pii: 6537625
doi: 10.1093/neuonc/noac057
pmc: PMC9629424
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Meta-Analysis
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1950-1961Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
J Clin Oncol. 2004 Mar 1;22(5):846-53
pubmed: 14990640
J Clin Oncol. 1999 Apr;17(4):1212
pubmed: 10561181
Int J Cancer. 2017 Aug 1;141(3):621-635
pubmed: 28463397
Pediatr Blood Cancer. 2010 Mar;54(3):377-83
pubmed: 20063410
Neuro Oncol. 2017 Nov 29;19(12):1661-1672
pubmed: 29048505
Neuro Oncol. 2010 Dec;12(12):1318-25
pubmed: 20716594
Endocr Relat Cancer. 2010 Jun 03;17(3):R141-59
pubmed: 20453080
J Clin Oncol. 2004 Feb 15;22(4):706-13
pubmed: 14966095
J Neurooncol. 1997 Mar;32(1):71-80
pubmed: 9049865
NCHS Data Brief. 2016 Sep;(257):1-8
pubmed: 27648773
Eur J Cancer. 2020 Sep;136:186-194
pubmed: 32711377
J Clin Oncol. 1996 Nov;14(11):2908-15
pubmed: 8918487
J Clin Oncol. 2015 Aug 1;33(22):2464-71
pubmed: 26101244
J Clin Oncol. 2019 Feb 10;37(5):396-402
pubmed: 30576269
J Neurooncol. 2020 May;147(3):721-730
pubmed: 32297094
J Neurosurg Pediatr. 2009 May;3(5):392-6
pubmed: 19409018
Cancer. 2003 Jul 15;98(2):369-76
pubmed: 12872359
J Clin Oncol. 2019 Dec 1;37(34):3283-3290
pubmed: 31545689
Am J Clin Oncol. 2012 Jun;35(3):279-83
pubmed: 21383606
J Neurooncol. 2011 Jan;101(1):109-15
pubmed: 20532955